close
close

Experts hail new schizophrenia drug Cobenfy as groundbreaking and “first of its kind”

British scientists have welcomed the US approval of a new drug for schizophrenia, saying it has “the potential to transform the lives of millions of people”.

The “major advance” in treatment offers a completely new drug approach to treating the condition, which can cause terrifying hallucinations, delusions and social withdrawal.

The US Food and Drug Administration (FDA) has approved the new drug Cobenfy, owned by the American pharmaceutical company Bristol Myers Squibb.

The FDA's approval was based on data from two studies that showed patients experienced fewer symptoms of schizophrenia.

Experts hope the new schizophrenia drug could help patients who don't respond well to existing treatments. Photo: Shutterstock
The drug is the first approved antipsychotic to target receptors in the brain and body associated with the cholinergic neurotransmitter system, which plays a key role in learning and memory, digestion and heartbeat control. Blood pressuremovement and other functions.